Loading…
← CockpitCompetitor Analysis › 1789.TW Scinopharm Taiwan, Ltd.Open in the cockpit ↗

Scinopharm Taiwan, Ltd.1789.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology
Momentum strong 77
Mkt cap
$435M
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$447,058
20-day average traded
Fwd P/E
39.4×
forward earnings
ROIC−WACC
-6.0 pp
WACC 5.0%
Hurdle
+2 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · TWDNT$18.75
1D-2.1%
1W-6.2%
1M-4.8%
3M+1.6%
6M-1.8%
YTD+11.9%
1Y+7.8%
ATR %3.6%
52w lowhigh35.6% off high

What Scinopharm Taiwan does

No business profile yet.

Scinopharm Taiwan at a glance

Size Scinopharm Taiwan (1789.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $435M, the 474th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$18.75 on 18 Nov 2026.

Performance Over six months the shares fell 1.8%, against -19.5% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 4.8% over the last twelve months (peer median -1.4%); the operating margin is -3.6% (peer median -17.2%).

Valuation It trades at 39.4× forward earnings against a peer median of 30.1× (2nd most expensive of 5).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 6.0 points below its cost of capital (5.0% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 20261789.TW 98Peer median 80
Six months, rebased to 100: Scinopharm Taiwan against the median of its 20 peers (local-currency closes).

Scinopharm Taiwan financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$3.04BNT$3.16BNT$3.41BNT$3.19BNT$3.26B
Revenue growth—-7%+7%-2%—
Gross profitNT$727MNT$988MNT$1.21BNT$1.13BNT$1.15B
EBITDANT$405MNT$626MNT$809MNT$776MNT$845M
Net incomeNT$16.7MNT$137MNT$339MNT$287MNT$353M
Free cash flowNT$512MNT$306MNT$471M-NT$37.2MNT$530M
Capital expenditureNT$204MNT$298MNT$300MNT$285MNT$250M
Total debtNT$902MNT$763MNT$677MNT$621MNT$678M

Quarterly statements and history in the cockpit →

Scinopharm Taiwan competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-20%0%603739000710IRLAPRTA25096712ARVN65896547688317115180476830CADL456160688163EPRX041960STTK69981789.TW6-month return →1-month return →
Up and to the right = strong over both horizons. Scinopharm Taiwan is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×50×100×150×6037392509671265471789.TWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Scinopharm Taiwan is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%603739671268831769981789.TWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Scinopharm Taiwan is the large dot.

Scinopharm Taiwan competitors and peer comparison

How Scinopharm Taiwan compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Scinopharm Taiwan against its 20 peers (data as of 18 Nov 2026)
Measure1789.TWPeer medianRank in peer set
1-month return-4.8%-13.3%4th highest of 21
6-month return-1.8%-19.5%5th highest of 21
Distance from 52-week high-35.6%-45.7%5th highest of 21
Revenue growth (TTM)-4.8%-1.4%8th lowest of 18
Operating margin-3.6%-17.2%7th highest of 17
Forward P/E39.4×30.1×2nd most expensive of 5
Growth the price implies (Req g, 7 yrs)2.1%4.0%3rd least demanding of 6
Growth delivered (Del g)+0.5%+38.9%2nd lowest of 5
Hurdle (Req g minus delivered)+1.6 pp-32.4 pp2nd most demanding of 5
ROIC minus cost of capital-6.0 pp-11.2 pp7th highest of 16
EV / EBITDA29.8×n/a—
Net debt / EBITDA-5.5×-0.6×2nd least indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%39.4×2.1%+0.5%
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%33.9×7.7%+7.3%
Berry Genomics 000710.SZChina$439M-17%-2%-24%n/an/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Prothena PRTAUnited States$429M-11%+347%-73%n/an/an/a
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%10.2×-19.5%n/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%26.2×5.3%+70.5%
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%n/an/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%170.0×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%n/a4.0%-62.3%
Qurient 115180.KSSouth Korea$452M-56%-14%-512%n/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%n/an/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%n/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%n/an/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%n/an/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%n/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%n/a-15.3%+197.3%

Questions

Which companies are Scinopharm Taiwan's closest peers?
The cockpit's peer set: Qingdao Vland Biotech (603739.SS), Berry Genomics (000710.SZ), IRulya Therapeutics (IRLA), Prothena (PRTA), Qyuns Therapeutics (2509.HK), Ever Supreme Bio Technology (6712.TWO), Arvinas (ARVN), EirGenix (6589.TW).
Is Scinopharm Taiwan expensive compared with its peers?
On forward p/e it trades at 39.4× against a peer median of 30.1×, 2nd most expensive of 5 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Scinopharm Taiwan stock performed?
Over six months to 18 Nov 2026 the shares returned -1.8% against -19.5% for the median peer; over one year +7.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.